BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Breitbach CJ, Lichty BD, Bell JC. Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine. 2016;9:31-36. [PMID: 27407036 DOI: 10.1016/j.ebiom.2016.06.046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Cassidy T, Craig M. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization. PLoS Comput Biol 2019;15:e1007495. [PMID: 31774808 DOI: 10.1371/journal.pcbi.1007495] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
2 Tarasova IA, Tereshkova AV, Lobas AA, Solovyeva EM, Sidorenko AS, Gorshkov V, Kjeldsen F, Bubis JA, Ivanov MV, Ilina IY, Moshkovskii SA, Chumakov PM, Gorshkov MV. Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. Oncotarget 2018;9:1785-802. [PMID: 29416731 DOI: 10.18632/oncotarget.22751] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bretscher C, Marchini A. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Viruses 2019;11:E562. [PMID: 31216641 DOI: 10.3390/v11060562] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
4 Bendjama K, Quemeneur E. Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. Hum Vaccin Immunother 2017;13:1997-2003. [PMID: 28846477 DOI: 10.1080/21645515.2017.1334746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aitken AS, Roy DG, Martin NT, Sad S, Bell JC, Bourgeois-Daigneault MC. Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice. J Immunother 2018;41:125-9. [PMID: 29293165 DOI: 10.1097/CJI.0000000000000208] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
6 Santiago DN, Heidbuechel JPW, Kandell WM, Walker R, Djeu J, Engeland CE, Abate-Daga D, Enderling H. Fighting Cancer with Mathematics and Viruses. Viruses 2017;9:E239. [PMID: 28832539 DOI: 10.3390/v9090239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM. Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Res 2018;78:922-37. [PMID: 29259007 DOI: 10.1158/0008-5472.CAN-15-3308] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
8 Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ. Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective. Front Oncol 2017;7:127. [PMID: 28695108 DOI: 10.3389/fonc.2017.00127] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
9 Felt SA, Grdzelishvili VZ. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. J Gen Virol 2017;98:2895-911. [PMID: 29143726 DOI: 10.1099/jgv.0.000980] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
10 Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. Designer Oncolytic Adenovirus: Coming of Age. Cancers (Basel) 2018;10:E201. [PMID: 29904022 DOI: 10.3390/cancers10060201] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
11 Weiss RA. Tumour-inducing viruses. Br J Hosp Med (Lond) 2016;77:565-8. [PMID: 27723397 DOI: 10.12968/hmed.2016.77.10.565] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. Mol Ther 2018;26:2315-25. [PMID: 30005865 DOI: 10.1016/j.ymthe.2018.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
13 Addou S, Sarkozy C, Lazarovici J, Champiat S, Stamatoullas A, Jardin F, Ribrag V, Marabelle A, Michot JM. Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation? Hum Vaccin Immunother 2021;:1-9. [PMID: 34101538 DOI: 10.1080/21645515.2021.1924521] [Reference Citation Analysis]
14 Cassidy T, Humphries AR. A mathematical model of viral oncology as an immuno-oncology instigator. Math Med Biol 2020;37:117-51. [PMID: 31329873 DOI: 10.1093/imammb/dqz008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM. The Role of Oncolytic Viruses in the Treatment of Melanoma. Curr Oncol Rep 2018;20:80. [PMID: 30145781 DOI: 10.1007/s11912-018-0729-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
16 Muscolini M, Castiello L, Palermo E, Zevini A, Ferrari M, Olagnier D, Hiscott J. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis. J Virol 2019;93:e00626-19. [PMID: 31092575 DOI: 10.1128/JVI.00626-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, Muik A. CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma. Oncotarget 2018;9:12971-81. [PMID: 29560124 DOI: 10.18632/oncotarget.24191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
18 Hummel J, Bienzle D, Morrison A, Cieplak M, Stephenson K, DeLay J, Woods JP, Lichty BD, Bridle BW. Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats. Sci Rep 2017;7:15738. [PMID: 29146945 DOI: 10.1038/s41598-017-15992-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology 2018;7:e1503032. [PMID: 30524901 DOI: 10.1080/2162402X.2018.1503032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
20 Loewe D, Dieken H, Grein TA, Weidner T, Salzig D, Czermak P. Opportunities to debottleneck the downstream processing of the oncolytic measles virus. Crit Rev Biotechnol 2020;40:247-64. [PMID: 31918573 DOI: 10.1080/07388551.2019.1709794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
21 Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K, Chattopadhyay S, Chandra D, Chilukuri N, Betapudi V. Gene Therapy Leaves a Vicious Cycle. Front Oncol. 2019;9:297. [PMID: 31069169 DOI: 10.3389/fonc.2019.00297] [Cited by in Crossref: 96] [Cited by in F6Publishing: 76] [Article Influence: 48.0] [Reference Citation Analysis]
22 Al-Zaher A, Domingo-Calap P, Sanjuán R. Experimental virus evolution in cancer cell monolayers, spheroids, and tissue explants. Virus Evol 2021;7:veab045. [PMID: 34040797 DOI: 10.1093/ve/veab045] [Reference Citation Analysis]
23 Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 2018;6:140. [PMID: 30514385 DOI: 10.1186/s40425-018-0458-z] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 25.7] [Reference Citation Analysis]
24 Rouanet M, Lebrin M, Gross F, Bournet B, Cordelier P, Buscail L. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. Int J Mol Sci 2017;18:E1231. [PMID: 28594388 DOI: 10.3390/ijms18061231] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
25 [DOI: 10.1101/585711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M. Innovative Therapy, Monoclonal Antibodies and Beyond. Cytokine Growth Factor Rev 2017;38:1-9. [PMID: 29029813 DOI: 10.1016/j.cytogfr.2017.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Menotti L, Avitabile E. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.Int J Mol Sci. 2020;21. [PMID: 33167582 DOI: 10.3390/ijms21218310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
28 Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer. 2018;6:78. [PMID: 30081947 DOI: 10.1186/s40425-018-0381-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 17.0] [Reference Citation Analysis]
29 Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology 2018;7:e1445459. [PMID: 29900060 DOI: 10.1080/2162402X.2018.1445459] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
30 Warner SG, O'Leary MP, Fong Y. Therapeutic oncolytic viruses: clinical advances and future directions. Curr Opin Oncol 2017;29:359-65. [PMID: 28678032 DOI: 10.1097/CCO.0000000000000388] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
31 Olagnier D, Lababidi RR, Hadj SB, Sze A, Liu Y, Naidu SD, Ferrari M, Jiang Y, Chiang C, Beljanski V, Goulet ML, Knatko EV, Dinkova-Kostova AT, Hiscott J, Lin R. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity. Mol Ther 2017;25:1900-16. [PMID: 28527723 DOI: 10.1016/j.ymthe.2017.04.022] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
32 Rico J, Perez C, Hernandez J, Guerrero C, Acosta O. Cell surface heat shock protein-mediated entry of tumor cell-adapted rotavirus into U-937 cells. Folia Microbiol (Praha) 2021;66:623-38. [PMID: 33950511 DOI: 10.1007/s12223-020-00845-x] [Reference Citation Analysis]
33 Lin CZ, Xiang GL, Zhu XH, Xiu LL, Sun JX, Zhang XY. Advances in the mechanisms of action of cancer-targeting oncolytic viruses. Oncol Lett 2018;15:4053-60. [PMID: 29541169 DOI: 10.3892/ol.2018.7829] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
34 Khalifa AM, Elsheikh MA, Khalifa AM, Elnaggar YSR. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. J Control Release 2019;311-312:125-37. [PMID: 31476342 DOI: 10.1016/j.jconrel.2019.08.034] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 15.5] [Reference Citation Analysis]
35 Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Front Immunol 2018;9:866. [PMID: 29755464 DOI: 10.3389/fimmu.2018.00866] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 31.3] [Reference Citation Analysis]
36 Taipale K, Tähtinen S, Havunen R, Koski A, Liikanen I, Pakarinen P, Koivisto-Korander R, Kankainen M, Joensuu T, Kanerva A, Hemminki A. Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget 2018;9:6320-35. [PMID: 29464075 DOI: 10.18632/oncotarget.23967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
37 Lee YS, Lee WS, Kim CW, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, Chon HJ, Kim C. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. J Immunother Cancer 2020;8:e000857. [PMID: 33199510 DOI: 10.1136/jitc-2020-000857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology 2018;7:e1412902. [PMID: 29721366 DOI: 10.1080/2162402X.2017.1412902] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 18.3] [Reference Citation Analysis]
39 Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Mol Ther Oncolytics 2021;20:459-69. [PMID: 33718594 DOI: 10.1016/j.omto.2021.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
40 Hwang JK, Hong J, Yun CO. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. Int J Mol Sci 2020;21:E8627. [PMID: 33207653 DOI: 10.3390/ijms21228627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
41 Atherton MJ, Stephenson KB, Nikota JK, Hu QN, Nguyen A, Wan Y, Lichty BD. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine 2018;36:2181-92. [PMID: 29544689 DOI: 10.1016/j.vaccine.2018.02.070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
42 Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD. Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother 2018;7:117-28. [PMID: 30538968 DOI: 10.2147/OV.S154494] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
43 Maroun J, Muñoz-Alía M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. Future Virol 2017;12:193-213. [PMID: 29387140 DOI: 10.2217/fvl-2016-0129] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 16.8] [Reference Citation Analysis]